106 related articles for article (PubMed ID: 7678671)
1. Effects of high doses of A-74273, a novel nonpeptidic and orally bioavailable renin inhibitor.
Verburg KM; Polakowski JS; Kovar PJ; Klinghofer V; Barlow JL; Stein HH; Mantei RA; Fung AK; Boyd SA; Baker WR
J Cardiovasc Pharmacol; 1993 Jan; 21(1):149-55. PubMed ID: 7678671
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs.
Wessale JL; Calzadilla SV; Boyd SA; Baker WR; Stein HH; Kovar PJ; Barlow J; Klinghofer V; Mantei R; Kleinert HD
J Cardiovasc Pharmacol; 1993 Oct; 22(4):644-52. PubMed ID: 7505369
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a well-absorbed, efficacious renin inhibitor, A-74273.
Kleinert HD; Stein HH; Boyd S; Fung AK; Baker WR; Verburg KM; Polakowski JS; Kovar P; Barlow J; Cohen J
Hypertension; 1992 Dec; 20(6):768-75. PubMed ID: 1452292
[TBL] [Abstract][Full Text] [Related]
4. Disparity between blood pressure and PRA inhibition after administration of a renin inhibitor to anesthetized dogs: methodological considerations.
Palmer RK; Rapundalo ST; Batley BL; Barnes AE; Singh S; Ryan MJ; Taylor DG
Clin Exp Hypertens; 1993 Jul; 15(4):663-81. PubMed ID: 8374609
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys.
Shibasaki M; Usui T; Inagaki O; Asano M; Takenaka T
J Pharm Pharmacol; 1994 Jan; 46(1):68-72. PubMed ID: 8201530
[TBL] [Abstract][Full Text] [Related]
6. A novel nonpeptidic, orally active renin inhibitor.
Morishima H; Koike Y; Nakano M; Atsuumi S; Tanaka S; Funabashi H; Hashimoto J; Sawasaki Y; Mino N; Nakano M
Biochem Biophys Res Commun; 1989 Mar; 159(3):999-1005. PubMed ID: 2495004
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of YM-21095, a potent and highly specific renin inhibitor.
Shibasaki M; Asano M; Fukunaga Y; Usui T; Ichihara M; Murakami Y; Nakano K; Fujikura T
Am J Hypertens; 1991 Dec; 4(12 Pt 1):932-8. PubMed ID: 1815649
[TBL] [Abstract][Full Text] [Related]
8. Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs.
McMahon EG; Yang PC; Babler MA; Bittner SE; Suleymanov OD; Cain-Janicki KJ; Bedell LJ; Hanson GJ; Cook CS
Hypertension; 1995 Jul; 26(1):95-100. PubMed ID: 7607739
[TBL] [Abstract][Full Text] [Related]
9. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
10. KRI-1314: an orally effective inhibitor of human renin.
Etoh Y; Miyazaki M; Saitoh H; Toda N
Jpn J Pharmacol; 1993 Sep; 63(1):109-19. PubMed ID: 8271523
[TBL] [Abstract][Full Text] [Related]
11. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative].
Muneta S
Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
13. Effects of SQ 14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs.
Harris DN; Heran CL; Goldenberg HJ; High JP; Laffan RJ; Rubin B; Antonaccio MJ; Goldberg ME
Eur J Pharmacol; 1978 Oct; 51(4):345-9. PubMed ID: 213295
[TBL] [Abstract][Full Text] [Related]
14. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension.
Kobrin I; Viskoper RJ; Laszt A; Bock J; Weber C; Charlon V
Am J Hypertens; 1993 May; 6(5 Pt 1):349-56. PubMed ID: 8512659
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs.
Wessale JL; Kleinert HD; Calzadilla SV; Kovar PJ; Rosenberg SH
Am J Hypertens; 1993 Jun; 6(6 Pt 1):514-21. PubMed ID: 8343235
[TBL] [Abstract][Full Text] [Related]
16. Sustained reduction in blood pressure during chronic administration of a renin inhibitor to normotensive marmosets.
Wood JM; Baum HP; Jobber RA; Neisius D
J Cardiovasc Pharmacol; 1987; 10 Suppl 7():S96-8. PubMed ID: 2485073
[TBL] [Abstract][Full Text] [Related]
17. [Hypotensive action of human renin inhibitor KRI-1314 in the common marmoset].
Saitoh H; Etoh Y; Murakami M; Kubota T; Miyazaki M
Nihon Yakurigaku Zasshi; 1994 Apr; 103(4):161-73. PubMed ID: 8175079
[TBL] [Abstract][Full Text] [Related]
18. Ro 42-5892 is a potent orally active renin inhibitor in primates.
Fischli W; Clozel JP; el Amrani K; Wostl W; Neidhart W; Stadler H; Branca Q
Hypertension; 1991 Jul; 18(1):22-31. PubMed ID: 1830563
[TBL] [Abstract][Full Text] [Related]
19. Acute hemodynamic effects of ciprokiren, a novel renin inhibitor, in sodium-depleted dogs.
Clozel JP; Véniant M; Sprecher U; Fischli W
J Cardiovasc Pharmacol; 1995 Oct; 26(4):674-7. PubMed ID: 8569232
[TBL] [Abstract][Full Text] [Related]
20. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
